Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.
about
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsThe efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.Longitudinal changes in regional fat content in HIV-infected children and adolescents.Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.Quality of life in people living with HIV: a cross-sectional study in Ouagadougou, Burkina Faso.Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study.Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot studyA longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of useSelf-reported body fat change in HIV-infected men is a marker of decline in physical health-related quality of life with aging, independent of co-morbidityCytokine therapy or structured treatment interruptions in HIV infection: which is best?Body image in women with HIV: a cross-sectional evaluationRegional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda.Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis.Fat distribution in men with HIV infection.Early factors in successful anti-HIV treatment.Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men.Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders.Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapyHIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.HIV-related stigma within communities of gay men: a literature review.Safety of lopinavir/ritonavir for the treatment of HIV-infection.Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients.Effects of a Phone Call Intervention to Promote Adherence to Antiretroviral Therapy and Quality of Life of HIV/AIDS Patients in Baoshan, China: A Randomized Controlled Trial.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260sDepression longitudinally mediates the association of appearance concerns to ART non-adherence in HIV-infected individuals with a history of injection drug useBody image in older men with or at-risk for HIV infection.Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?Treatment options for lipodystrophy in HIV-positive patients.Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy statusMitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapySubjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.Assessing appearance-related disturbances in HIV-infected men who have sex with men (MSM): psychometrics of the body change and distress questionnaire-short form (ABCD-SF).
P2860
Q28088839-C6C33E0B-2A01-4033-9AD8-354EB51BBBDCQ33614139-FB2315A3-08D2-4D15-BB5A-1AAFFDDB8D24Q33693051-F1A521F9-213F-444E-8F4A-E4B494BD08C3Q33722450-2E4592BB-0EDF-4588-92A6-C6CD629745E9Q33851716-6405AE97-6F48-47F8-A673-B827B35336A6Q33984094-2B63EDAA-1553-4F79-8222-9DC7B10369BDQ33989249-8BCB9B6D-9DC9-43F8-BCD7-B391F1832596Q34161671-6ABE951C-E448-4D22-AE12-9796690EDF8CQ34522890-79E05819-4BE1-4F87-890C-EDDFFA4B80ECQ34593181-B5A77914-EBED-4E80-8A25-77F61BF913E8Q34601818-7A6C5ACD-40E2-43F6-946D-E9BBF3B2C604Q34660778-703602DD-98C7-43CD-B583-1165427B8880Q35005653-A951B432-56DB-4AB5-952A-8E5B88D341F8Q35173638-8BEB34CF-2873-451A-A3D1-1F77A9E05875Q35177350-C512EAC1-557B-452B-B851-02DE9A25FA40Q35194387-12716CBD-78DF-427B-9D51-6037567486A4Q35207282-B03E159A-E88D-4EE3-84D6-7281D5367B57Q35535757-6AB87BBE-7B84-4427-97D1-8D5D84DF41FCQ35575721-73FC11D6-DE1A-4A2A-A644-612E06C8A278Q35762427-4B9F88B5-79B5-426A-B317-2AC2A7977CC5Q35793287-4D9F638E-9FFB-462E-AD0F-1FBA33B61C23Q35803315-56B16261-370E-442E-AD14-290FC124C5E3Q35823452-624452D9-ACF3-4B6F-AB8A-0062F042DA85Q36007239-8EB61F9C-4788-496D-8655-3AA1D235DB67Q36047801-1EDA9120-4885-4203-9879-26B5F913DC24Q36150530-A93E68A8-C0B0-4DF8-898A-0BFD72FC136EQ36206201-19C5DC67-C332-421C-97B5-6B56C0CFBBECQ36376395-F2E95F7E-02F7-4C79-B458-009D35F81A39Q36582487-A18CC5A1-AE2E-482F-8CAE-2F45F1A4E15AQ36646867-4E589EF9-9071-4103-9934-D766D3BB2F67Q36676379-7052576B-EFEE-4BEA-B5D1-D2CDBB14C03AQ36691851-EB062B02-AC50-4BA1-A983-F399EF60223AQ36826050-CE37DE4C-EF26-416A-BD53-CD737A7CC5CFQ36909274-E86FD3EC-E4A5-4448-9B49-A416C57F1AD8Q36933854-5E368EA9-CA65-4877-BA63-A1994B266FECQ37030842-E12BF45E-DEFE-42ED-B6B2-CCE9F052401DQ37114196-23A325C5-026D-455D-B00F-5D1245FD2346Q37344333-FAD7A07A-E2C9-490B-B2A8-76767C97204EQ37437722-A420F2F7-717A-436F-8726-91B065081225Q37656287-0DC46BE8-514D-472A-9811-ECD324676F33
P2860
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Failure to maintain long-term ...... py: the role of lipodystrophy.
@en
Failure to maintain long-term ...... py: the role of lipodystrophy.
@nl
type
label
Failure to maintain long-term ...... py: the role of lipodystrophy.
@en
Failure to maintain long-term ...... py: the role of lipodystrophy.
@nl
prefLabel
Failure to maintain long-term ...... py: the role of lipodystrophy.
@en
Failure to maintain long-term ...... py: the role of lipodystrophy.
@nl
P2093
P1433
P1476
Failure to maintain long-term ...... py: the role of lipodystrophy.
@en
P2093
APROCO Study Group
J P Moatti
P Carrieri
V Cailleton
P304
P356
10.1097/00002030-200112070-00012
P407
P50
P577
2001-12-01T00:00:00Z